SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is trending due to a recently announced deal with Valio Technologies, which includes an equity investment and future revenue sharing, igniting fervent discussion among traders. This news, coupled with the stock's low float and high short interest, has triggered intense short-squeeze activity, drawing comparisons to other high-flying equities. The community is actively debating the potential for continued parabolic momentum, with many experiencing significant FOMO in this "AI" sector play.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies (QCLS) is sparking considerable community buzz following the appointment of an OpenAI expert to its board, validating its strategic pivot into quantum-class computing. This development, coupled with its innovative photonic technology, has ignited strong bullish sentiment among investors who anticipate significant short covering and a potential explosive run.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending following its acquisition of a critical minerals flotation facility, bolstering its role as the sole U.S. producer of antimony. The community is actively discussing strong institutional confidence, including significant recent share purchases, and the company's strategic importance in securing domestic supply chains for defense applications. This renewed focus on critical minerals positions the company for continued growth amidst a robust sector trend.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is a major talking point amid concerns over the NCAA's call for federal restrictions on college sports betting and the rising influence of prediction markets. Community sentiment is divided, with some investors highlighting recent strong state-level revenue figures and upcoming football season catalysts, while others express frustration over competitive pressures and price weakness.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending with surging volume, driven by community enthusiasm around its Breakthrough Therapy Designation (BTD) and Fast Track status for Pemvidutide, a MASH/obesity drug candidate. Many investors consider the stock significantly undervalued given its differentiated profile and de-risked pipeline, leading to widespread speculation about potential partnerships or a major acquisition. This strong bullish sentiment, coupled with an active debate around market manipulation and valuation, keeps the stock at the forefront of discussion.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to recent significant share purchases by CEO Ryan Cohen, coupled with strong anticipation for a new GME-focused publication from Michael Burry expected early next week. The community is buzzing with short squeeze speculation, closely watching weekend developments and "power hour" price action, with many believing current movements are setting the stage for a significant upward move.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the market keenly awaits the upcoming release of 3-year pivotal trial data for its ELEVIDYS gene therapy and a subsequent conference call, with many anticipating positive results. Community sentiment highlights significant undervaluation of the company's approved therapies and promising pipeline, fueling speculation of a potential short squeeze and a re-rating of the stock.

Americas Gold & Silver Corp. engages in the acquisition, exploration, development, and exploration of mineral resource properties. It operates through the following segments: Cosalá Operations, Galena Complex, Relief Canyon, and Corporate and Other. The Cosalá Operations segment operates in Mexico. The Galena Complex and Relief Canyon segments focuses on the United States. The company was founded by Peter Jude Hawley on May 12, 1998 and is headquartered in Toronto, Canada.

Americas Gold and Silver Corp

Americas Silver Corp

Americas Silver Corp is trending amidst a robust rally in silver prices and significant advancements in its antimony recovery, a critical mineral for domestic supply. The community is actively discussing the disconnect between physical and paper silver markets, anticipating substantial margin expansion, and recognizing USAS as a strategic player in vital mineral production. This strong sentiment is driven by surging industrial demand and perceived undervaluation within the broader precious metals sector.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending as the community reacts to the FDA's approval for using its commercially manufactured GP2 product in the FLAMINGO-01 trial, a significant de-risking step for future regulatory submissions. Many investors are expressing strong conviction, anticipating a potential short squeeze due to an exceptionally tight float and high insider ownership. The ongoing conversation highlights expectations for an eventual partnership or buyout as the company advances its promising breast cancer immunotherapy.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following its recent earnings report, which included weak guidance for the upcoming quarter due to ongoing supply constraints. This has spurred a polarized community discussion, with some investors concerned about the company's immediate valuation while others emphasize Intel's strategic national security role and long-term foundry ambitions despite short-term headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ETF Strategies to Follow Wall Street Forecasts Higher Bond Yields

ETF Strategies to Follow on Moody's Downgrade of U.S. Debt

Invesco Capital Management LLC - PowerShares UltraShort Lehman 20+ Year Treasury ProShares 2x Shares

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

Current Price	$34.43
Prev Close	$34.59
Open	$34.50
Dividend Yield	N/A
50-Day Moving Average	$34.28
Beta	N/A
Avg. Volume	328,559.32
PE Ratio	N/A

52-Week High	$39.70
52-Week Low	$31.17
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

TBT
ProShares UltraShort 20+ Year Treasury ETF

Feed

News

Sentiment

Fundamentals

Info

Latest TBT News

TBTProShares UltraShort 20+ Year Treasury ETF